Neurodegenerative Disease: From Molecular Basis to Therapy, 2nd Edition

doi:10.3390/books978-3-7258-3507-2

Format

Hardback

License and Copyright

Keywords

?-synuclein; lipids; Parkinson’s disease; post-translational modification; SERCA; positive allosteric modulators; calcium; Alzheimer’s disease; beta-amyloid; dendritic spines; calcium imaging; long-term potentiation; exosome; nasal lavage fluid; 5XFAD; high-density multielectrode array; hippocampal slice; neural network; Alzheimer’s disease (AD); Aging-Associated Cognitive Decline (AACD); Amyloid Cascade Hypothesis 2.0 (ACH2.0); intraneuronal A? (iA?); A? protein precursor (A?PP); A?PP-independent iA? production pathway; ACH2.0-based drugs; BACE1/BACE2 activators; mRNAs; RNA sequencing; Parkinson’s disease; transcriptome analysis; substantia nigra; Alzheimer’s disease; regulatory T cells; Amyloid-?; status epilepticus; claustrum; endopiriform nucleus; claustroamygdaloid complex; neurodegeneration; ontogeny; polycystic ovary syndrome; PCOS; amyloid-associated proteins; Alzheimer’s disease; Alzheimer’s disease (AD); conventional AD; unconventional AD; amyloid cascade hypothesis (ACH); ACH-based models of AD; ACH-based AD drugs; ACH2.0; ACH2.0-based models of AD; intraneuronal A? (iA?); A? protein precursor (A?PP); A?PP-independent iA? production pathway; histamine; dihydroergotamine; Morris water maze; novel object recognition; terminal nerve; olfactory dysfunctions; Kallmann syndrome; GnRH; SARS-CoV-2; Parkinson’s disease; lactacystin; GRP78; ER stress; neuroprotection; substantia nigra; microglia; Alzheimer’s disease; artemisinins; multitargeting neurotherapeutics; antisense oligonucleotides (ASOs); motor neuron diseases; spinal muscular atrophy; amyotrophic lateral sclerosis; spinal and bulbar muscular atrophy; innovative therapy; nusinersen; tofersen; clinical trials; chronic inflammation; immune activation; neutrophil; extracellular traps; low-level LPS; IP injection; peripheral; brain; flow cytometry; microscopy; C57BL/6J; mice; timepoint optimization; inflammation; matrix metalloproteinase-3; RNA sequencing; ingenuity pathway analysis; gene set enrichment analysis; stroke; transcriptome; n/a

Reprint

Download Flyer

Neurodegenerative Disease: From Molecular Basis to Therapy, 2nd Edition

Edited by

March 2025

378 pages

ISBN978-3-7258-3508-9 (Hardback)
ISBN978-3-7258-3507-2 (PDF)

https://doi.org/10.3390/books978-3-7258-3507-2

Free Download (PDF)

This is a Reprint of the Special Issue Neurodegenerative Disease: From Molecular Basis to Therapy, 2nd Edition that was published in

Biology & Life Sciences

Chemistry & Materials Science

Medicine & Pharmacology

Summary

This Special Issue addresses the problem of treating neurodegenerative diseases from a variety of perspectives, from basic research into the molecular mechanisms responsible for a disease to reviews of the most advanced therapies available. This topic can provide exciting insights into new therapeutic approaches for various neurodegenerative disorders, expanding our knowledge on the biological basis and clinical research, as well as new challenges and future perspectives in neurodegeneration.

Related Books

February 2024

Neurodegeneration in Cognitive Impairment and Mood Disorders for Experimental, Clinical and Translational Neuropsychiatry

Medicine & Pharmacology

The recommendations have been generated using an AI system.

Neurodegenerative Disease: From Molecular Basis to Therapy, 2nd Edition

Related Books

Neurodegenerative Disease: From Molecular Basis to Therapy

New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders

Neurodegenerative Diseases

Novel Therapies of Oxidative Stress-Induced Age-Related Neurodegenerative Diseases

Neurodegeneration in Cognitive Impairment and Mood Disorders for Experimental, Clinical and Translational Neuropsychiatry